Home › Duchenne Muscular Dystrophy › California › Sacramento
Duchenne Muscular Dystrophy clinical trials in Sacramento, CA
5 studies for Duchenne Muscular Dystrophy are looking for participants at sites in and around Sacramento (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
RecruitingObservational study
- University of California, Davis, Sacramento
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
RecruitingPhase 1
- University of California, Davis, Sacramento
Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials
RecruitingObservational study
- UC Davis, Sacramento
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
RecruitingPhase 1/2
- University of California, Davis, Sacramento
Duchenne Electronic Health Record Study
RecruitingObservational study
- UC Davis Health, Sacramento
Duchenne Muscular Dystrophy trials in other cities
- Little Rock, AR7 studies
- Durham, NC5 studies
- Chicago, IL5 studies
- Washington, DC5 studies
- Gainesville, FL5 studies
- Boston, MA5 studies
- Nashville, TN4 studies
- Columbus, OH4 studies
- Seattle, WA3 studies
- Los Angeles, CA3 studies
- Norfolk, VA3 studies
- St. Louis, MO3 studies
Other studies in Sacramento
- Non-Small Cell Lung Cancer29 studies
- Lung Cancer22 studies
- Breast Cancer20 studies
- Prostate Cancer19 studies
- Metastatic Cancer16 studies
- Acute Myeloid Leukemia12 studies
- Heart Failure12 studies
- Pancreatic Cancer12 studies
- Cancer (all types)11 studies
- Colon Cancer11 studies
- Bladder Cancer10 studies
- Colorectal Cancer10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.